0.35

0.00% +0.00

Cybin Inc (CYBN)

Overview News Price History Discussions Forecast

Cybin Inc stock is currently priced at $0.35, with a 24-hour trading volume of 2.73M. It has seen a +0.00% increased in the last 24 hours and a -24.42% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.3478 pivot point. If it approaches the $0.3537 resistance level, significant changes may occur.

Previous Close:

$0.35

Open:

$0.3526

24h Volume:

2.73M

Market Cap:

$265.91M

Revenue:

Net Income/Loss:

$-52.07M

P/E Ratio:

-1.8051

EPS:

-0.1939

Net Cash Flow:

$-44.93M

1W Performance:

+0.00%

1M Performance:

-24.42%

6M Performance:

-41.23%

1Y Performance:

+8.02%

1D Range:

$0.3451

$0.3589

52W Range:

$0.21

$0.738

Cybin Inc Stock (CYBN) Company Profile

Name

Cybin Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

908 764 8385

Address

100 King Street West, Suite 5600, Toronto

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CYBN's Discussions on Twitter

Cybin Inc Stock (CYBN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Cybin Inc Stock (CYBN) Latest News

Cybin Inc Stock (CYBN) Financials Data

Cybin Inc (CYBN) Net Income 2024

CYBN net income (TTM) was -$52.07 million for the quarter ending December 31, 2023, a -30.04% decrease year-over-year.

Cybin Inc (CYBN) Cash Flow 2024

CYBN recorded a free cash flow (TTM) of -$44.93 million for the quarter ending December 31, 2023, a -20.73% decrease year-over-year.

Cybin Inc (CYBN) Earnings per Share 2024

CYBN earnings per share (TTM) was -$0.2077 for the quarter ending December 31, 2023, a +10.13% growth year-over-year.

Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.